Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing precision oncology medicines. Founded in 2018, the company's mission is to address the unmet needs of cancer patients by leveraging its proprietary precision medicine platform. Headquartered in Watertown, Massachusetts, Acrivon also maintains biomarker discovery efforts in Lund, Sweden.

The company's core technology is the Acrivon Predictive Precision Proteomics (AP3) platform, which enables the creation of drug-specific OncoSignature companion diagnostics. This platform is designed to identify patients whose tumors are predicted to be sensitive to specific treatments, moving beyond genomics-based patient selection. Acrivon's pipeline is focused on DNA Damage Response, cell cycle, and transcriptional regulators. Its lead candidate, ACR-368 (also known as Prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a registrational-intent Phase 2b clinical trial for endometrial cancer and platinum-resistant ovarian cancer. Other key candidates include ACR-2316, a selective, dual WEE1/PKMYT1 inhibitor in Phase 1 development, and ACR-6840, a preclinical development candidate targeting CDK11.

Recent notable developments include positive Phase 2b data for ACR-368 in endometrial cancer, and the company has received FDA Fast Track designation for ACR-368 as monotherapy in endometrial cancer, along with Breakthrough Device designation for its OncoSignature assay. Peter Blume-Jensen, M.D., Ph.D., serves as the Founder, President, and CEO. In 2025, Mansoor Raza Mirza, M.D., was appointed Chief Medical Officer, and Adam Levy, Ph.D., M.B.A., became Chief Financial Officer. As a clinical-stage, pre-revenue company, Acrivon Therapeutics is focused on advancing its pipeline through research and development, with analysts projecting potential for significant growth based on its clinical data and platform advancements.